Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2024 | Story André Damons | Photo Suplied
Dr Claudia Ntsapi
Dr Matlakala C Ntsapi is a Senior Lecturer and researcher in the Department of Basic Medical Sciences at the UFS.

A researcher from the University of the Free State (UFS) is investigating the potential benefits of medicinal plants as supplementary treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

The work of Dr Matlakala Claudia Ntsapi, Senior Lecturer in the Department of Basic Medical Sciences at the UFS, focuses on preserving human brain health to delay or prevent age-related conditions.

According to her, while the primary focus is on age-related neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, the bioactive compounds in these medicinal plants may also have therapeutic potential for other neurological disorders, various types of cancers and Type 2 Diabetes. The broad protective effects of these plant-based bioactive compounds could make them relevant in the potential treatment of other diseases involving oxidative stress and inflammation.

She is involved in several multidisciplinary projects, collaborating with research experts from Denmark, the UK, and various national institutions such as the Central University of Technology (CUT), North West University (NWU), and the Stellenbosch University (SUN), as well as colleagues from the UFS. 

The potential of medicinal plants

“In collaboration with experts from our institution, the CUT and SU, who have strong backgrounds in pharmacology and ethnobotany, we are focusing on underexplored medicinal plants and nutraceuticals. These plants contain bioactive compounds with potential neuroprotective properties, which are believed to provide extra health benefits beyond basic nutritional value,” says Dr Ntsapi.

“We hope that these medicinal plants have the potential to preserve cognitive function and slow the progression of neurodegenerative diseases like Alzheimer’s. Specifically, we aim to identify novel therapeutic targets and discover new avenues for intervention that can improve the quality of life for individuals affected by age-related brain conditions,” she says.

Identifying therapeutic targets and discovering new interventions

The bioactive compounds found in selective medicinal plants and nutraceuticals, explains Dr Ntsapi, serve as a promising source of ‘natural’ therapeutics that may be safer and have fewer side effects compared to conventional synthetic drugs. Additionally, the untapped potential of these compounds for neuroprotection and the preservation of brain health could provide innovative therapeutic solutions. These compounds may be used as complementary therapies to existing drugs, which often have limited efficacy on their own, thereby enhancing overall treatment outcomes for neurodegenerative diseases.

“By utilising cutting-edge techniques, such the innovative CelVivo ClinoStar 2 System, we strive to gain insights into the safety and efficacy of underexplored medicinal plants in preserving cognitive function and slowing disease progression.

“By exploring the untapped potential of bioactive compounds found in medicinal plants and nutraceuticals, our research group aims to contribute to the identification of novel therapeutic targets and the discovery of new avenues for intervention to improve the quality of life for individuals affected by age-related brain conditions,” says Dr Ntsapi.

The researchers, in collaboration with others in the UFS School of Clinical Medicine, will develop 3D cell-based models of the human cortex and hippocampus by utilising the CelVivo ClinoStar 2 System. This cutting-edge technology, housed in an easy-to-use CO² incubator, mimics ‘animal model-like’ conditions with low sheer stress, allowing scientists to generate cell-based models that closely resemble real-world conditions.

Dr Ntsapi explains that they will specifically focus on the technologies’ applications in studying age-related neurodegenerative disorders, such as Alzheimer’s disease. The potential impact of this research is immense, as it could contribute to the development of novel therapeutic strategies for combating the debilitating progression of neurodegenerative diseases, and ultimately improving the quality of life for affected individuals.

Hope for the research

“Our hope for this research is to significantly advance our understanding of neurodegenerative disease progression and to develop novel therapeutic strategies that can effectively combat these debilitating conditions. Ultimately, we aim to improve the quality of life for individuals affected by neurodegenerative diseases by preserving cognitive function and slowing disease progression.

“This research will contribute to the knowledge pool in this field, with the potential to lead to groundbreaking discoveries in the treatment of Alzheimer’s disease and other related disorders, potentially contributing to the policy guidelines on how these conditions are managed and treated,” she says.

The international partners from Denmark and the UK have made their expertise and facilities available to postgraduate students from the UFS, some of whom they are co-supervising.

Dr Ntsapi, who is passionate about exploring innovative solutions to address the gradual decline in normal brain function associated with aging, was this year one the university’s nominations for the prestigious 2023/2024 NSTF-South32 Awards, popularly known as the “Science Oscars” of South Africa. 

News Archive

Two Kovsie women involved in international sports events
2012-05-14

 

Hetsie Veitch and Ebeth Grobbelaar
Photo: René-Jean van der Berg
14 May 2012

The organisers of two international sports events will depend on the expertise of two Kovsie women to make the events a major success.

The honour to be involved in international sports event has befallen Ms Hetsie Veitch and Ms Ebeth Grobbelaar.

The honour is the result of many years’ hard work and devotion in their respective fields.

In June, when the USA chooses the team to represent it at the 2012 Paralympic Games in London, Ms Veitch will be one of the classifiers who will determine in which categories athletes may compete.

Ms Veitch, Head of the Unit for Students with Disabilities at the University of the Free State (UFS), has been invited to be a member of the Classification Panel at the final USA Paralympic athletics trials. The trials take place from 27 June to 1 July 2012 in Indianapolis, Indiana, in the USA.

Ms Veitch and four other classifiers, two from Brazil, one from Canada and one from the USA, will test and verify the international classification status of the American athletes. No athlete will be allowed to take part without their classification being verified by the panel.

Ms Veitch, who recently achieved the status of International Paralympic Committee (IPC) Athletics Classifier, the highest achievement for a classifier in sport for the disabled, said that this category of sport has always been her passion.

“To have the opportunity to be involved in the classification of the USA team for the London 2012 Paralympic Games is a huge honour. I am going to start working on being chosen for the official IPC classification panel for the 2016 Paralympic Games in Brazil.”

Ms Grobbelaar, Assistant Director of the South African Testing Laboratory for Prohibited Substances at the UFS, was invited to be involved in the Drugs Control Centre in the unit against prohibited substances which will test sportsmen and women during this year’s Olympic Games in London.

Ms Grobbelaar said that even though the future of sportsmen and women would be in her hands, she is totally capable of carrying out the task that awaits her.

“I will be part of the laboratory team who will test the athletes’ samples for prohibited substances. I was part of the South African team who tested samples in our own laboratory in 2010 during the FIFA Soccer World Cup, as well as for the All Africa Games. The task is one I perform every day in our own laboratories. Each sample that I analyse determines an athlete’s future. The circumstances during the Olympic Games are different, but the work remains the same.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept